Clinical Edge Journal Scan

Long-term exposure to trihalomethanes in drinking and swimming pool water increases the risk for CLL


 

Key clinical point: Long-term exposure to brominated trihalomethanes (THM) in drinking water and swimming pool water is associated with increased odds of developing chronic lymphocytic leukemia (CLL).

Major finding: The odds of developing CLL increased by 22% for every 10 μg/L increase in the level of brominated THM in drinking water (adjusted odds ratio [aOR] 1.22; 95% CI 1.14-1.31). Swimming pool users vs non-users (swimming pool attendance ≥ 10 times vs < 10 times in life) had significantly increased odds of CLL (aOR 2.38; 95% CI 1.61-3.52).

Study details: This multicentric multicase-control study included 170 patients with CLL (age 20-85 years) and 1442 matched population-based control individuals without CLL.

Disclosures: This study was funded by European Commission grants and others. The authors declared no conflicts of interest.

Source: Donat-Vargas C et al. Lifetime exposure to brominated trihalomethanes in drinking water and swimming pool attendance are associated with chronic lymphocytic leukemia: A multicase-control study in Spain (MCC-Spain). J Expo Sci Environ Epidemiol. 2023 (Sep 19). doi: 10.1038/s41370-023-00600-7

Recommended Reading

Commentary: Genetics, prognosis score, and PI3K in MCL, October 2023
B-Cell Lymphoma ICYMI
Second-line axi-cel therapy yields high response rates in high-risk relapsed or refractory LBCL
B-Cell Lymphoma ICYMI
Second-line vs later-line zanubrutinib improves survival in relapsed or refractory MCL
B-Cell Lymphoma ICYMI
High-dose methotrexate does not reduce CNS progression risk in high-risk aggressive BCL
B-Cell Lymphoma ICYMI
Ibrutinib maintenance after frontline induction is effective in mantle cell lymphoma
B-Cell Lymphoma ICYMI
Ibrutinib and bortezomib combo durably effective in relapsed or refractory MCL with high-risk features
B-Cell Lymphoma ICYMI
Cumulative airborne dioxin exposure increases CLL and SLL risk
B-Cell Lymphoma ICYMI
Upfront ASCT overcomes the survival advantage provided by pre-transplant HDAC induction in MCL
B-Cell Lymphoma ICYMI
Acalabrutinib and zanubrutinib have similar efficacy in CLL, shows a matching-adjusted indirect comparison
B-Cell Lymphoma ICYMI
CAR T-cell therapy safe for older patients with relapsed or refractory DLBCL
B-Cell Lymphoma ICYMI